For individuals with adenocarcinoma, large cell carcinoma and NOS for whom the rate of PD-L1 positivity is ≥ 1% and in whom no other gene mutations are present, carboplatin or cisplatin as well as pemetrexed and pembrolizumab are recommended treatments. The gene discussed is CD274; the disease is adenocarcinoma.